CONMED (CNMD) CEO Pat Beyer receives new RSU and stock option awards

Rhea-AI Filing Summary

Beyer Pat reported acquisition or exercise transactions in this Form 4 filing.

CONMED Corp President & CEO Pat Beyer received new equity awards, increasing her direct holdings through compensation grants rather than open‑market trades. On March 2, 2026, she was granted 28,800 RSUs, each representing a right to one CONMED common share, and 68,258 stock options.

The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% the second year, and 34% the third year under CONMED’s 2025 Long-Term Incentive Plan. The stock options were also granted under the 2025 plan and generally vest in equal 25% installments over four years, beginning one year after the grant date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Beyer Pat

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	RSUs (Restricted Stock Units)	28,800	$0.00	--
Grant/Award	Options To Purchase Common Stock	68,258	$0.00	--

Holdings After Transaction: RSUs (Restricted Stock Units) — 28,800 shares (Direct); Options To Purchase Common Stock — 68,258 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year. The stock options were granted under CONMED Corporation Corporation's 2025 Long-Term Incentive Plan, with the stock options generally vesting in equal amounts over a four-year period with the first 25% of the stock options vesting one year after the grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beyer Pat

(Last) (First) (Middle)

C/O CONMED CORPORATION

11311 CONCEPT BOULEVARD

(Street)

LARGO FL 33773

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
RSUs (Restricted Stock Units)	$0	03/02/2026		A		28,800		(1)	03/02/2036	Common Stock	28,800	$0	28,800	D
Options To Purchase Common Stock	$45.79	03/02/2026		A		68,258		(2)	03/02/2036	Common Stock	68,258	$0	68,258	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.

2. The stock options were granted under CONMED Corporation Corporation's 2025 Long-Term Incentive Plan, with the stock options generally vesting in equal amounts over a four-year period with the first 25% of the stock options vesting one year after the grant date.

	/s/ Thomas Fistek for Pat Beyer by Power of Attorney	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CONMED (CNMD) report for Pat Beyer?

CONMED reported that President & CEO Pat Beyer received equity compensation grants, not market trades. She was awarded 28,800 restricted stock units and 68,258 stock options on March 2, 2026, under the company’s 2025 Long-Term Incentive Plan, increasing her direct equity-based interests.

How many RSUs did CONMED (CNMD) grant to CEO Pat Beyer?

Pat Beyer received 28,800 restricted stock units from CONMED. Each RSU represents a contingent right to one share of CONMED common stock. These RSUs were granted under the 2025 Long-Term Incentive Plan and are designed to vest over a multi-year period tied to continued service.

What is the vesting schedule for Pat Beyer’s CONMED (CNMD) RSUs?

The RSUs granted to Pat Beyer generally vest over three years. About 33% vest one year after the grant date, another 33% in the second year, and the remaining 34% in the third year, subject to the terms of CONMED’s 2025 Long-Term Incentive Plan.

How many stock options did CONMED (CNMD) grant to Pat Beyer and how do they vest?

CONMED granted Pat Beyer 68,258 stock options. These options were issued under the 2025 Long-Term Incentive Plan and generally vest in four equal annual installments of 25% each, starting one year after the grant date, encouraging longer-term alignment with shareholders.

Were Pat Beyer’s CONMED (CNMD) equity awards open-market purchases or compensation grants?

Pat Beyer’s reported equity awards were compensation grants, not open-market purchases. The Form 4 shows RSUs and stock options with a transaction code “A” for grant or award acquisition, both issued at a stated price of $0.00 per unit under CONMED’s 2025 plan.

Does Pat Beyer hold CONMED (CNMD) RSUs and options directly or indirectly?

The filing indicates Pat Beyer holds the reported RSUs and stock options directly. The ownership type is marked as direct, with no footnotes describing any trust, partnership, or other entity, meaning the awards are attributed personally to the President & CEO.